These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 25940985)

  • 1. Head and neck cancer: second-line afatinib shows promise.
    Killock D
    Nat Rev Clin Oncol; 2015 Jul; 12(7):373. PubMed ID: 25940985
    [No Abstract]   [Full Text] [Related]  

  • 2. EGFR inhibition for recurrent or metastatic HNSCC.
    Argiris A
    Lancet Oncol; 2015 May; 16(5):488-9. PubMed ID: 25892143
    [No Abstract]   [Full Text] [Related]  

  • 3. Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial.
    Clement PM; Gauler T; Machiels JP; Haddad RI; Fayette J; Licitra LF; Tahara M; Cohen EE; Cupissol D; Grau JJ; Guigay J; Caponigro F; de Castro G; de Souza Viana L; Keilholz U; Del Campo JM; Cong XJ; Ehrnrooth E; Vermorken JB;
    Ann Oncol; 2016 Aug; 27(8):1585-93. PubMed ID: 27084954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer.
    Cohen EEW; Licitra LF; Burtness B; Fayette J; Gauler T; Clement PM; Grau JJ; Del Campo JM; Mailliez A; Haddad RI; Vermorken JB; Tahara M; Guigay J; Geoffrois L; Merlano MC; Dupuis N; Krämer N; Cong XJ; Gibson N; Solca F; Ehrnrooth E; Machiels JH
    Ann Oncol; 2017 Oct; 28(10):2526-2532. PubMed ID: 28961833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Afatinib as second-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Subgroup analyses of treatment adherence, safety and mode of afatinib administration in the LUX-Head and Neck 1 trial.
    Haddad R; Guigay J; Keilholz U; Clement PM; Fayette J; de Souza Viana L; Rolland F; Cupissol D; Geoffrois L; Kornek G; Licitra L; Melichar B; Ribaldo Nicolau U; Rauch D; Zanetta-Devauges S; Cohen EEW; Machiels JP; Tahara M; Vermorken J; Geng Y; Zografos E; Gauler T
    Oral Oncol; 2019 Oct; 97():82-91. PubMed ID: 31450171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination therapy with bevacizumab and temsirolimus in squamous cell carcinoma of the head and neck.
    Bhatt VR; Ganti AK
    Oral Oncol; 2013 Aug; 49(8):e25. PubMed ID: 23631847
    [No Abstract]   [Full Text] [Related]  

  • 7. Oral metronomic chemotherapy in recurrent, metastatic and locally advanced head and neck cancers.
    Patil V; Noronha V; Krishna V; Joshi A; Prabhash K
    Clin Oncol (R Coll Radiol); 2013 Jun; 25(6):388. PubMed ID: 23434353
    [No Abstract]   [Full Text] [Related]  

  • 8. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected].
    Stewart JS; Cohen EE; Licitra L; Van Herpen CM; Khorprasert C; Soulieres D; Vodvarka P; Rischin D; Garin AM; Hirsch FR; Varella-Garcia M; Ghiorghiu S; Hargreaves L; Armour A; Speake G; Swaisland A; Vokes EE
    J Clin Oncol; 2009 Apr; 27(11):1864-71. PubMed ID: 19289630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methotrexate, vinblastine, epidoxorubicin, and bleomycin as second-line chemotherapy for recurrent and/or metastatic squamous cell carcinoma of the head and neck.
    Gebbia V; Valenza R; Testa A; Borsellino N; Cannata G; Restivo S; Speciale R; Ingria F; Spadafora G; Gebbia N
    ORL J Otorhinolaryngol Relat Spec; 1994; 56(5):279-82. PubMed ID: 7526312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Failure of anti-EGFR therapy in p16-positive head and neck cancer.
    Roesler R; Schwartsmann G
    Lancet Oncol; 2013 Oct; 14(11):e436-e437. PubMed ID: 24079865
    [No Abstract]   [Full Text] [Related]  

  • 11. [The efficacy of polychemotherapy with cisplatin, methotrexate and 5-fluorouracil in inoperable forms of squamous cell cancer of the head and neck area].
    Karaseva VV; Stepanov VG; Korolev VV
    Vopr Onkol; 1992; 38(2):205-8. PubMed ID: 1300707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Indications for cytostatic therapy of recurrent cancer].
    Schröder M; Stennert E; von Heyden HW; Scherpe A
    HNO; 1984 Jun; 32(6):245-8. PubMed ID: 6206035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alternating regimens in recurrent and metastatic squamous cell carcinoma of the head and neck.
    Cognetti F; Molinari A; Carlini P; Frassineti GL; Pinnarò P; Marangolo M
    Oncology; 1987; 44(5):270-2. PubMed ID: 2444912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Failure of anti-EGFR therapy in p16-positive head and neck cancer - authors' reply.
    Vermorken JB; Bach BA
    Lancet Oncol; 2013 Oct; 14(11):e437-e438. PubMed ID: 24079867
    [No Abstract]   [Full Text] [Related]  

  • 15. A phase I-II trial of cisplatin and dichloromethotrexate in squamous cell cancer of the head and neck.
    Wheeler RH; Natale RB; Roshon SG; Baker SR
    J Clin Oncol; 1984 Jul; 2(7):831-5. PubMed ID: 6539813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective randomized trial of one-hour sequential versus simultaneous methotrexate plus 5-fluorouracil in advanced and recurrent squamous cell head and neck cancer.
    Browman GP; Archibald SD; Young JE; Hryniuk WM; Russell R; Kiehl K; Levine MN
    J Clin Oncol; 1983 Dec; 1(12):787-92. PubMed ID: 6366132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EGFR-directed treatments in SCCHN.
    Vokes EE; Seiwert TY
    Lancet Oncol; 2013 Jul; 14(8):672-3. PubMed ID: 23746667
    [No Abstract]   [Full Text] [Related]  

  • 18. Alternating combination chemotherapy using cisplatin-bleomycin with sequential methotrexate-5-FU plus leucovorin rescue in patients with head and neck cancer.
    Panasci L; Gravenor D; Black M; Frenkiel S; Margolese R
    Cancer Treat Rep; 1985 Sep; 69(9):1015-7. PubMed ID: 2411401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of recurrent head and neck cancer with cisplatin and 5-fluorouracil vs. the same plus bleomycin and methotrexate.
    Amrein PC; Fabian RL
    Laryngoscope; 1992 Aug; 102(8):901-6. PubMed ID: 1379664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of methotrexate and 5-FU for recurrent head and neck cancer.
    Jacobs C
    Cancer Treat Rep; 1982 Nov; 66(11):1925-8. PubMed ID: 6754074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.